White E G, Smith D H, Zaphiropoulos G C
Br J Rheumatol. 1984 Feb;23(1):57-60. doi: 10.1093/rheumatology/23.1.57.
One hundred and ninety-one patients treated with gold and penicillamine over a seven-year period were reviewed retrospectively for the occurrence of haematuria. Over this period 10% had shown haematuria, and in over half of these an identifiable cause was found. In the remaining patients, a clear relationship with their treatment seemed likely in only two. Penicillamine therapy was discontinued in all patients with unexplained haematuria, but two patients have continued to show haematuria. Gold therapy has been continued in the presence of haematuria without ill effect. There has been no deterioration in renal function in those patients who have continued to show unexplained haematuria and at no time was proteinuria an accompanying feature.
对191例在7年期间接受金制剂和青霉胺治疗的患者进行回顾性研究,以观察血尿的发生情况。在此期间,10%的患者出现了血尿,其中一半以上的患者找到了可识别的病因。在其余患者中,似乎只有两例与治疗有明确关系。所有不明原因血尿的患者均停用了青霉胺治疗,但仍有两名患者持续出现血尿。在有血尿的情况下继续使用金制剂治疗,未产生不良影响。那些持续出现不明原因血尿的患者肾功能没有恶化,且蛋白尿从未作为伴随症状出现。